Optima Capital’s Emergent Biosolutions EBS Stock Holding History

Optima Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-55	Closed	-$680	–	486
2025 Q4	$680	Buy	+55	New	+$589	﹤0.01%	1029

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Optima Capital's EBS Position: Q1 2026 in Review

Optima Capital sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 55 shares — an estimated $680 sold.

Optima Capital first reported a position in EBS in Q4 2025 and held it in 1 quarter. The position peaked at $680 in Q4 2025. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

Optima Capital reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
Optima Capital sold 55 Emergent Biosolutions shares in Q1 2026, an estimated $680.
Optima Capital first reported a position in Emergent Biosolutions in Q4 2025 and held it in 1 quarter.
Optima Capital's Emergent Biosolutions position peaked at $680 in Q4 2025.
190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Optima Capital's 13F filing for Q1 2026, filed 5 May 2026.